Welcome to our dedicated page for Beyondspring SEC filings (Ticker: BYSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BeyondSpring Inc. (NASDAQ: BYSI) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a clinical-stage biopharmaceutical company. This SEC filings page aggregates those disclosures and, with AI-powered summaries, helps investors interpret the information most relevant to BeyondSpring’s oncology pipeline and capital structure.
Core filings include the annual report on Form 10‑K, which contains audited consolidated financial statements, notes on research and development spending, general and administrative expenses, net loss from continuing operations, and the presentation of SEED Therapeutics as discontinued operations. Current reports on Form 8‑K document material events such as quarterly financial results, equity offerings under an effective shelf registration statement, updates on the sale of BeyondSpring’s Series A‑1 preferred shares in SEED Therapeutics, and scheduling of the annual meeting of shareholders.
Investors can also review proxy materials, such as the definitive proxy statement on Schedule 14A, which outlines matters submitted to shareholder vote, including ratification of the independent registered public accounting firm. Additional 8‑K filings describe share purchase agreements, lock-up provisions for investors in registered offerings, and changes in BeyondSpring’s ownership percentage in SEED following new financing rounds.
Stock Titan’s AI tools assist by highlighting key elements in lengthy filings: trends in research and development and general and administrative expenses, cash and cash equivalents, deferred revenue, shareholders’ deficit, and noncontrolling interests. The platform also flags items related to capital raises, registration statements, and governance events. Real-time integration with EDGAR means new 10‑K, 8‑K, S‑3, and proxy filings for BYSI appear quickly, while AI-generated overviews help readers understand how each document fits into BeyondSpring’s broader clinical and financing strategy.
BeyondSpring Inc. director Matthew Kirkby received a grant of stock options covering 23,902 ordinary shares. The options have an exercise price of $1.64 per share and expire on April 1, 2036. All options vest on April 1, 2027, contingent on his continuous service with the company.
BeyondSpring Inc. director Patrick Fabbio received a grant of stock options covering 22,165 ordinary shares. The options have an exercise price of $1.64 per share and were issued under the company’s 2017 Omnibus Incentive Plan as part of his compensation.
All 22,165 options vest on April 1, 2027, provided he continues serving the company through that date, and they expire on April 1, 2036. This is a compensation-related award, not an open-market purchase or sale of BeyondSpring shares.
BeyondSpring Inc. director Brendan Delaney received a grant of stock options for 20,427 ordinary shares on April 1, 2026 as equity compensation. The options have an exercise price of $1.64 per share and expire on April 1, 2036. All options vest on April 1, 2027, subject to his continuous service with the company through that date.
BeyondSpring Inc. director Majeti Jiangwen received a grant of stock options to purchase 21,730 Ordinary Shares of the company. These options have an exercise price of $1.64 per share and expire on April 1, 2036.
All of the options will vest on April 1, 2027, provided the director continues to serve the company through that date. Following this grant, the Form 4 shows holdings of 21,730 stock options directly owned.
BeyondSpring Inc. reported that Chief Scientific Officer Lu Yingjuan June received a grant of stock options for 17,840 ordinary shares. The options have an exercise price of $1.64 per share and expire on April 1, 2036.
According to the grant terms, 4,460 options will vest on each of April 1, 2027, April 1, 2028, April 1, 2029 and April 1, 2030, as long as she continues serving the company through those dates. All options were reported as directly owned following this award.
BeyondSpring Inc. director and Chief Executive Officer Huang Lan received a grant of stock options to acquire 11,514 Ordinary Shares. The options have an exercise price of $1.804 per share and were awarded at no cost to the reporting person.
According to the grant terms, 2,878 options will vest on each of April 1, 2027, April 1, 2028 and April 1, 2029, and 2,880 options will vest on April 1, 2030, subject to continuous service with the company. The options expire on April 1, 2031. This is a compensation-related award rather than an open-market purchase or sale.
Xu Sihai reported acquisition or exercise transactions in this Form 4 filing.
BeyondSpring Inc. director Xu Sihai received a grant of stock options covering 18,689 ordinary shares. The options have a strike price of $1.64 per share and expire on April 1, 2036.
According to the grant terms, all of these stock options vest on April 1, 2027, provided Xu continues to serve with the company through that date. This award increases his directly held derivative position to 18,689 options and reflects compensation rather than an open-market purchase or sale.
BeyondSpring Inc. reports another year of operating losses as it advances its oncology pipeline. The company generated no revenue in 2025 and recorded a consolidated net loss of $14.2 million, narrowing from $16.7 million in 2024, with losses driven by research and development and general and administrative expenses.
Cash and cash equivalents from continuing operations were $7.8 million as of December 31, 2025, while net cash used in operating activities increased to $19.8 million. The balance sheet shows total assets of $25.9 million against total liabilities of $49.9 million, resulting in a shareholders’ deficit of $24.0 million.
BeyondSpring continues to focus on Plinabulin, a first-in-class small molecule for non-small cell lung cancer and other cancers, supported by positive Phase 3 data (DUBLIN-3) and multiple investigator-initiated trials. It also retains an equity stake in SEED Therapeutics, which is advancing a targeted protein degradation platform and has initiated a Phase 1 study of its RBM39 degrader.
Management states it expects ongoing losses and indicates that additional capital—through equity, debt, partnerships, or asset sales—will be required to fund development and operating needs, with potential dilution and other financing constraints highlighted as key risks.
BeyondSpring Inc. reports another year of operating losses as it advances its oncology pipeline. The company generated no revenue in 2025 and recorded a consolidated net loss of $14.2 million, narrowing from $16.7 million in 2024, with losses driven by research and development and general and administrative expenses.
Cash and cash equivalents from continuing operations were $7.8 million as of December 31, 2025, while net cash used in operating activities increased to $19.8 million. The balance sheet shows total assets of $25.9 million against total liabilities of $49.9 million, resulting in a shareholders’ deficit of $24.0 million.
BeyondSpring continues to focus on Plinabulin, a first-in-class small molecule for non-small cell lung cancer and other cancers, supported by positive Phase 3 data (DUBLIN-3) and multiple investigator-initiated trials. It also retains an equity stake in SEED Therapeutics, which is advancing a targeted protein degradation platform and has initiated a Phase 1 study of its RBM39 degrader.
Management states it expects ongoing losses and indicates that additional capital—through equity, debt, partnerships, or asset sales—will be required to fund development and operating needs, with potential dilution and other financing constraints highlighted as key risks.
BeyondSpring Inc. reported full-year 2025 results and highlighted major clinical milestones for its lead cancer drug Plinabulin and equity affiliate SEED Therapeutics. For continuing operations, research and development expenses rose to $4.4 million from $2.6 million, while general and administrative expenses decreased to $4.6 million from $6.1 million. Net loss from continuing operations was $8.7 million, similar to $8.9 million in 2024, and cash, cash equivalents and short-term investments totaled $12.6 million as of December 31, 2025. Including discontinued operations related to SEED, net loss was $14.2 million, but net loss attributable to BeyondSpring narrowed sharply to $1.0 million, with basic and diluted loss per share improving to $0.02 from $0.28. Clinically, Phase 3 DUBLIN-3 data in EGFR wild-type NSCLC showed a statistically significant overall survival benefit for Plinabulin plus docetaxel versus docetaxel alone, with a hazard ratio of 0.72 and a 2.5-month median overall survival improvement, and supported plans for the global Phase 3 DUBLIN-4 confirmatory trial. Early combination studies suggested Plinabulin may help overcome resistance to PD-1/PD-L1 therapies. SEED advanced its RBM39 degrader ST‑01156 into Phase 1a trials, secured U.S. Orphan Drug and Rare Pediatric Disease designations, and completed a $30 million Series A‑3 financing.
BeyondSpring Inc. reported full-year 2025 results and highlighted major clinical milestones for its lead cancer drug Plinabulin and equity affiliate SEED Therapeutics. For continuing operations, research and development expenses rose to $4.4 million from $2.6 million, while general and administrative expenses decreased to $4.6 million from $6.1 million. Net loss from continuing operations was $8.7 million, similar to $8.9 million in 2024, and cash, cash equivalents and short-term investments totaled $12.6 million as of December 31, 2025. Including discontinued operations related to SEED, net loss was $14.2 million, but net loss attributable to BeyondSpring narrowed sharply to $1.0 million, with basic and diluted loss per share improving to $0.02 from $0.28. Clinically, Phase 3 DUBLIN-3 data in EGFR wild-type NSCLC showed a statistically significant overall survival benefit for Plinabulin plus docetaxel versus docetaxel alone, with a hazard ratio of 0.72 and a 2.5-month median overall survival improvement, and supported plans for the global Phase 3 DUBLIN-4 confirmatory trial. Early combination studies suggested Plinabulin may help overcome resistance to PD-1/PD-L1 therapies. SEED advanced its RBM39 degrader ST‑01156 into Phase 1a trials, secured U.S. Orphan Drug and Rare Pediatric Disease designations, and completed a $30 million Series A‑3 financing.
BeyondSpring Inc. major shareholders Lan Huang and Linqing Jia have jointly reported beneficial ownership of 6,048,488 ordinary shares, equal to 15% of the company’s outstanding stock. The filing aggregates shares held through British Virgin Islands entities, personal holdings, grantor retained annuity trusts, a charitable foundation, and irrevocable trusts for Dr. Huang’s children.
The percentage is calculated against 40,322,320 ordinary shares outstanding as of September 30, 2025, as disclosed in BeyondSpring’s Form 10-Q. Huang and Jia report shared voting power over all 6,048,488 shares and shared dispositive power over 1,231,804 of those shares.